The Hypothalamic-Pituitary-Adrenal Axis in Borderline Personality Disorder: A Review

被引:52
作者
Zimmerman, Daniel J.
Choi-Kain, Lois Wonsun [1 ]
机构
[1] McLean Hosp, Belmont, MA 02478 USA
关键词
borderline personality disorder; cortisol; corticotropin-releasing hormone; dexamethasone suppression test; hypothalamic-pituitary-adrenal axis; stress; DEXAMETHASONE-SUPPRESSION TEST; CORTICOTROPIN-RELEASING-HORMONE; POSTTRAUMATIC-STRESS-DISORDER; LIFE EVENTS; FOLLOW-UP; MAJOR DEPRESSION; HPA-AXIS; PARTIAL HOSPITALIZATION; TYROSINE-HYDROXYLASE; PRENATAL STRESS;
D O I
10.1080/10673220902996734
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: borderline personality disorder (BPD) is a psychiatric diagnosis characterized by high exposure, reactivity, and vulnerability to stress. Given these abnormalities in stress reactivity in BPD, there is a question of whether the hypothalamic-pituitary-adrenal (HPA) axis functions normally in BPD, since the activation of the HPA axis normally occurs to coordinate both behavioral and physiologic responses to stress. Several studies have investigated the functioning of the HPA axis in BPD and have shown varied results. This review seeks to summarize and interpret the findings of this growing literature. Methods: Pubmed search for English language articles on borderline personality disorder and hypothalamic-pituitary-adrenal axis. Results: findings are mixed but suggest that important variables relevant to between-group differences include comorbid depression, comorbid posttraumatic stress disorder, dissociative symptoms, and history of childhood abuse. Discussion: comorbid diagnoses and clinical features such as trauma history and symptom severity may have variable, interacting influences on the psychoneuroendocrine profile in BPD. Also explored here are the implications of these findings for developing possible models of HPA-axis dysfunction in BPD, for identifying potential targets for treatment, and for improving the methodology of future studies.
引用
收藏
页码:167 / 183
页数:17
相关论文
共 113 条
[1]  
[Anonymous], 1987, Am J Psychiatry, V144, P1253
[2]  
ARANA GW, 1985, ARCH GEN PSYCHIAT, V42, P1193
[3]   ELEVATED CSF CRF IN SUICIDE VICTIMS [J].
ARATO, M ;
BANKI, CM ;
BISSETTE, G ;
NEMEROFF, CB .
BIOLOGICAL PSYCHIATRY, 1989, 25 (03) :355-359
[4]   Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress [J].
Bale, TL ;
Contarino, AB ;
Smith, GW ;
Chan, R ;
Gold, LH ;
Sawchenko, PE ;
Koob, GF ;
Vale, WW ;
Lee, KF .
NATURE GENETICS, 2000, 24 (04) :410-414
[5]   Effectiveness of partial hospitalization in the treatment of borderline personality disorder: A randomized controlled trial [J].
Bateman, A ;
Fonagy, P .
AMERICAN JOURNAL OF PSYCHIATRY, 1999, 156 (10) :1563-1569
[6]   Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: An 18-month follow-up [J].
Bateman, A ;
Fonagy, P .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (01) :36-42
[7]  
BAXTER L, 1984, J CLIN PSYCHIAT, V45, P150
[8]   DEXAMETHASONE SUPPRESSION TEST IN HOSPITALIZED DEPRESSED-PATIENTS WITH BORDERLINE PERSONALITY-DISORDER [J].
BEEBER, AR ;
KLINE, MD ;
PIES, RW ;
MANRING, JM .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1984, 172 (05) :301-303
[9]   STEPPS: A cognitive-behavioral systems-based group treatment for outpatients with borderline personality disorder - A preliminary report [J].
Blum, N ;
Pfohl, B ;
St John, D ;
Monahan, P ;
Black, DW .
COMPREHENSIVE PSYCHIATRY, 2002, 43 (04) :301-310
[10]   THE ANTIDEPRESSANTS FLUOXETINE, IDAZOXAN AND PHENELZINE ALTER CORTICOTROPIN-RELEASING HORMONE AND TYROSINE-HYDROXYLASE MESSENGER-RNA LEVELS IN RAT-BRAIN - THERAPEUTIC IMPLICATIONS [J].
BRADY, LS ;
GOLD, PW ;
HERKENHAM, M ;
LYNN, AB ;
WHITFIELD, HJ .
BRAIN RESEARCH, 1992, 572 (1-2) :117-125